0001624326 false 0001624326 2023-03-14 2023-03-14 0001624326 PAVM:CommonStockParValue0.001PerShareMember 2023-03-14 2023-03-14 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2023-03-14 2023-03-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares














Date of Report (Date of earliest event reported): March 14, 2023


(Exact Name of Registrant as Specified in Charter)


Delaware   001-37685   47-1214177

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


360 Madison Avenue, 25th Floor   10017
(Address of Principal Executive Offices)   (Zip Code)


Registrant’s telephone number, including area code: (212) 949-4319


(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share   PAVM   The Nasdaq Stock Market LLC
Series Z Warrants to Purchase Common Stock   PAVMZ   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 2.02. Results of Operations and Financial Condition.


On March 14, 2023, PAVmed Inc. (the “Company”) issued a press release announcing financial results for its fiscal year ended December 31, 2022 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.


Item 7.01. Regulation FD Disclosure.


The disclosure set forth under Item 2.02 is incorporated herein by reference.


The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits:


Exhibit No.   Description
99.1   Press release.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: March 15, 2023 PAVMED INC.
  By: /s/ Dennis McGrath
    Dennis McGrath
    President and Chief Financial Officer



EX-99.1 2 ex99-1.htm


Exhibit 99.1


PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results


Conference call and webcast to be held tomorrow, March 15th at 8:30 AM EST


NEW YORK, March 14, 2023 - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the year ended December 31, 2022.


Conference Call and Webcast


The webcast will be available at the investor relations section of the Company’s website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 877-550-1858 and international listeners should dial 1-848-488-9160. All listeners should provide the operator with the conference call name “PAVmed, Inc. Business Update Conference Call” to join.


Those seeking further details on Lucid are encouraged to visit the company’s website at luciddx.com to view the webcast of its business update call held yesterday, and its corresponding press release.


Business Update Highlights


“Over the past two months, the PAVmed team has executed on its strategic restructuring plan to protect long-term shareholder interests during challenging market conditions by tightly focusing its efforts and resource allocation on near-term commercial activities and milestones,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “The plan is working and appears to have been right-sized—extending cash runway while assuring the commercial efforts are adequately resourced. Lucid continues to deliver steady EsoGuard test volume growth through organic sales and now high-volume testing events and is gaining traction with commercial payors. Veris’ momentum is accelerating with an exciting commercial product, strong customer interest and a powerful business model which is not dependent on securing third-party reimbursement. I am proud how the team has battled through these challenges and emerged stronger with a bright commercial future for what remains a diversified portfolio.”


Highlights from the fourth quarter and recent weeks include:


In January 2022, PAVmed launched a strategic restructuring initiative designed to maximize cash runway and protect long-term shareholder interests through adjustments in near-term strategic priorities and associated resource allocation. The Company stated that it would focus substantially all its resources and near-term efforts on accelerating the commercialization of Lucid’s and Veris’ products, resulting in a meaningful reduction in its workforce and quarterly cash burn. The strategic initiative has been completed resulting in a durable, positive impact on the consolidated cash runway and balance sheet, which were further strengthened by Lucid’s announcement yesterday that it had secured $24.6 million in financing extending its cash runway well into 2024.




In December 2022, Veris, PAVmed’s digital health subsidiary, focused on enhancing personalized cancer care through remote patient monitoring (RPM), commercially launching its Veris Cancer Care Platform™ (“Veris CCP”), and executing its first commercial contract with New Jersey Cancer Care, PA (“NJCC”), a leading oncology practice and member of the prestigious Quality Cancer Care Alliance.


In February 2023, the Veris Cancer Care Platform™ (Veris CCP) went live following successful onboarding of the first cohort of cancer patients and their clinicians. Enrolled patients received a VerisBox™ and began connecting their Bluetooth-enabled health care devices to transmit real-time physiologic data to the cloud-based Veris CCP clinician portal. The patients also began reporting symptoms and quality-of-life parameters through the Veris CCP patient smartphone app, which became available for patients on the Apple App Store and Google Play. The cloud-based clinician portal was integrated into the oncology practice and the cancer care team began using it to review physiologic and clinical data and other RPM services for which they can bill. The software-as-a-service recurring-revenue business model is now poised to deliver near-term value at attractive margins to both Veris and its clients.


Veris is now focused on optimizing the patient and clinician experience, achieving high patient compliance, and streamlining the integration processes as its commercial team drives adoption and delivers new accounts. Feedback and interest in Veris CCP from oncology practices and cancer care centers is strong, focusing on Veris CCP as tool to enhance personalized care and as well as practice economics through RPM.


Veris has made steady progress on development and regulatory milestones for its implantable physiologic monitor and is targeting a commercial launch next year. The device, which is designed to be implanted in conjunction with a chemotherapy vascular access port, will further the power of the Veris CCP platform by assuring near perfect patient compliance with RPM data reporting requirements.


Yesterday, Lucid provided a detailed update of its commercial and financial performance. Quarterly EsoGuard testing volume continues along a steady growth path, both sequentially and annually. Satellite Lucid Test Center (sLTC) activity, whereby Lucid clinicians collect samples at physician offices, continues to increase rapidly, with Lucid clinicians now performing the majority of cell collection procedures either in an LTC or sLTC.




Lucid’s commercial payor engagement is accelerating, particularly with its signing of an in-network agreement with MultiPlan®, the largest secondary Preferred Provider Organization (PPO), expanding EsoGuard’s access to include Multiplan’s estimated 60 million consumers. EsoGuard pricing is holding, with in-network contracts, averaging more than $2000 per test and all in-network PPO contracts priced at or above the Medicare payment rate of $1938. Key drivers of future in-network commercial payor contracting—generating claims history with individual payors and collecting retrospective and prospective clinical utility data—are also progressing well.


Lucid continues to expand its commercial horizons bringing EsoGuard testing directly to at-risk patients at high-volume testing day events and launching a direct contracting strategic initiative to engage directly with large Administrative Services Only (ASO) self-insured employers, unions, and other entities.


Financial Results


For the fourth quarter of 2022, EsoGuard related revenues were $0.1 million while for the year ended December 31, 2022, revenues were $0.4 million. Fourth-quarter and full-year 2022 operating expenses were approximately $24.6 million and $91.3 million, respectively, which include stock-based compensation expenses of $4.9 million and $19.5 million, respectively. GAAP net loss attributable to shareholders for the fourth quarter and full-year 2022 were approximately $20.5 million and $89.2 million, or $(0.23) and $(1.00) per common share.


As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company’s financial results, the Company’s preliminary non-GAAP adjusted loss for the fourth quarter and year ended December 31, 2022, were approximately $13.8 million and $54.0 million or $(0.15) and $(0.61) per common share.


PAVmed had cash and cash equivalents of $39.7 million as of December 31, 2022, compared with $77.3 million as of December 31, 2021.


PAVmed Non-GAAP Measures


To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.


Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.


Non-GAAP financial measures are provided to enhance readers’ overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.




A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three months and year ended December 31, 2022, and 2021 is as follows:



For the three months ended

December 31,


For the year ended

December 31,

   2022   2021   2022   2021 
Revenue  $112   $300   $377   $500 
Operating expenses   24,616    19,979    91,304    54,893 
Other (Income) Expense   68    -    12,311    1,733 
Net Loss   24,572    19,679    103,238    56,126 
Net income (loss) per common share, basic and diluted  $(0.23)  $(0.21)  $(1.00)  $(0.42)
Net loss attributable to common stockholders   (20,532)   (17,285)   (89,264)   (50,630)
Preferred Stock dividends and deemed dividends   71    67    281    283 
Net income (loss) as reported   (20,461)   (17,218)   (88,983)   (50,347)
Depreciation and amortization expense1   1,426    198    2,457    226 
Interest expense, net   223    -    1,272    53 
EBITDA   (18,812)   (17,020)   (85,254)   (50,068)
Other non-cash or financing related expenses:                    
Stock-based compensation expense2   4,949    4,380    19,532    15,009 
Debt extinguishment2   311    -    5,434    3,715 
Acquisition related   226    -    653    133 
Change in FV convertible debt   (466)   -    1,273    (1,682)
Offering costs convertible debt   -    -    4,332    - 
Other non-cash charges   -    -    -    (300)
Non-GAAP adjusted (loss)   (13,792)   (12,640)   (54,030)   (33,193)
Basic and Diluted shares outstanding   89,759    83,307    89,076    77,516 
Non-GAAP adjusted (loss) income per share  $(0.15)  $(0.15)  $(0.61)  $(0.43)


1 Included in general and administrative expenses in the financial statements.

2 Included in other income and expenses.




Non-GAAP Operating Expenses 

For the three months ended

December 31,


For the year ended

December 31,

   2022   2021   2022   2021 
Cost of revenue   1,618    441    3,614    585 
Stock-based compensation expense   (7)   -    (16)   - 
Net cost of revenue   1,611    441    3,598    585 
Amortization of acquired intangible assets   506    123    1,784    146 
Sales and marketing expense   5,759    3,340    19,318    8,895 
Stock-based compensation expense   (605)   (363)   (2,464)   (1,177)
Net sales and marketing expense   5,154    2,977    16,854    7,718 
General and administrative expense total   10,059    9,106    41,041    25,420 
Depreciation and amortization expense   (920)   (75)   (673)   (80)
Stock-based compensation expense   (3,985)   (3,711)   (16,001)   (12,799)
Net general and administrative expense   5,154    5,320    24,367    12,541 
Research and development expense total   6,674    6,969    25,547    19,847 
Stock-based compensation expense   (352)   (306)   (1,051)   (1,033)
Net research and development expense   6,322    6,663    24,496    18,814 
Total operating expenses   24,616    19,979    91,304    54,893 
Depreciation and amortization   (1,426)   (198)   (2,457)   (226)
Stock-based compensation expense   (4,949)   (4,380)   (19,532)   (15,009)
Net Non-GAAP operating expenses   18,241    15,401    69,315    39,658 


About PAVmed and its Subsidiaries


PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Its other majority-owned subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.


For more and for more information about PAVmed, please visit pavmed.com.


For more information about Lucid Diagnostics, please visit luciddx.com.


For more information about Veris Health, please visit verishealth.com.




Forward-Looking Statements


This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s clinical and preclinical studies; whether and when PAVmed’s products are cleared by regulatory authorities; market acceptance of PAVmed’s products once cleared and commercialized; PAVmed’s ability to raise additional funding as needed; and other competitive developments. In addition, PAVmed has been monitoring the COVID-19 pandemic and the pandemic’s impact on PAVmed’s businesses. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed’s control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s future operations, see Part I, Item 1A, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.


Investor and Media Contact:


Michael Parks

PAVmed and Lucid Diagnostics






EX-101.SCH 3 pavm-20230314.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 pavm-20230314_def.xml XBRL DEFINITION FILE EX-101.LAB 5 pavm-20230314_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, Par Value $0.001 Per Share Series Z Warrants to Purchase Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 pavm-20230314_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Mar. 14, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 14, 2023
Entity File Number 001-37685
Entity Registrant Name PAVMED INC.
Entity Central Index Key 0001624326
Entity Tax Identification Number 47-1214177
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 360 Madison Avenue
Entity Address, Address Line Two 25th Floor
Entity Address, Postal Zip Code 10017
City Area Code (212)
Local Phone Number 949-4319
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, Par Value $0.001 Per Share  
Title of 12(b) Security Common Stock, Par Value $0.001 Per Share
Trading Symbol PAVM
Security Exchange Name NASDAQ
Series Z Warrants to Purchase Common Stock  
Title of 12(b) Security Series Z Warrants to Purchase Common Stock
Trading Symbol PAVMZ
Security Exchange Name NASDAQ
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001624326 2023-03-14 2023-03-14 0001624326 PAVM:CommonStockParValue0.001PerShareMember 2023-03-14 2023-03-14 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2023-03-14 2023-03-14 iso4217:USD shares iso4217:USD shares 0001624326 false 8-K 2023-03-14 PAVMED INC. DE 001-37685 47-1214177 360 Madison Avenue 25th Floor 10017 (212) 949-4319 false false false false Common Stock, Par Value $0.001 Per Share PAVM NASDAQ Series Z Warrants to Purchase Common Stock PAVMZ NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 3 21 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pavmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-0548-EntityAddressCityOrTown-Missing] Submission type 8-K should have a non-empty value for EntityAddressCityOrTown in the Required Context. form8-k.htm [dq-0548-EntityAddressStateOrProvince, EntityAddressCountry-Inclusive] In submission type 8-K, at least one of EntityAddressStateOrProvince, EntityAddressCountry should have a value. form8-k.htm form8-k.htm ex99-1.htm pavm-20230314.xsd pavm-20230314_def.xml pavm-20230314_lab.xml pavm-20230314_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "pavm-20230314_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "pavm-20230314_lab.xml" ] }, "presentationLink": { "local": [ "pavm-20230314_pre.xml" ] }, "schema": { "local": [ "pavm-20230314.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 21, "memberCustom": 2, "memberStandard": 0, "nsprefix": "PAVM", "nsuri": "http://pavmed.com/20230314", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-14to2023-03-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://pavmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-14to2023-03-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "PAVM_CommonStockParValue0.001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Par Value $0.001 Per Share" } } }, "localname": "CommonStockParValue0.001PerShareMember", "nsuri": "http://pavmed.com/20230314", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "PAVM_SeriesZWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series Z Warrants to Purchase Common Stock" } } }, "localname": "SeriesZWarrantsToPurchaseCommonStockMember", "nsuri": "http://pavmed.com/20230314", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001493152-23-007682-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-007682-xbrl.zip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
? SXYD^^[,13*J(=TDG643I)2!@BZAR M#N>8Z@'I5&3:Q%K6[+%9VG.0S'&VHEFU M+0A2N3TX#"L8,<]<;"CU[%U%R6X3@G\HA+V'9?EF$WT#D[QT0$#;'F+Z]=X* M8F\)?X!MJCR MPHKGA&\W(&&!JJ?)2@$*)<%O"DFCM$]" 8IM!.HSZ!C.@([ M^X)3^_S/9YUT7O.WMJYD+%8_X_C>;M7.K!U:,D80>3935OE?#M*R2Q:)R<_: M/93#%+(> __1\#_00B+4N!9XI0L^Y'MOV+UDVGAVQXCW$S.:DY688[$O^\[; M]'6WIUM_6M,MI'N?Z3[ XE\Z_3N^O]^/K\P\D"G(@>- M6LMI-(^<1KO],L/@&[%:J_6/A7+\:FJ6;RJ"?:KQCUL4\T8@^(]% >/S6P:M MUVY\G2YC>W92K\\MOSO'7[SBMD%YLU;;5\H/#_>4\O;?X/G?6G/_'2[062!5WJ7(!;PJ=%R.O7.75]<-."ZJ*EWG>YA=U>HZ=:= M9JVU*]2T6\Y1MYF/FG5;CQ64^E:/Y@OM=!]\H"KFE^R=4?B_$Z_-Y@!N]6U6 M!ZY\(UDY=8Y6=)M6I6+_6%!Y\ARH-YQF?57_^1&SP3ELSD'6O;BP+9M\*WQ] M%A'[J+3>?R&!"] ^7#6T?<2ZVG4Z\[['TV-#K8D6_\GSH=UQZHTYQWCSV/4P M7IC!*WMB[ K(^9/.SGP=FUOX_"D'T>8>[Z73SL7K"W@+QUL7>[-OEPS"7,V M>L,DX)'>K7.A-8?^MY*PO=@8%7CA\>U$A[%&WM;2KCL6@Q7IM)NKQHZCV:><-OW[ALK,J N;"#QM[],0 M>$UZ^L?]M[&'1834F4NP/CD6-(X*-6@<[7>8O,B_Y-I>NW!O/S*7/6YUUNC+ MY;/'];GP:2OV^,CISJO5ENQQLS4'=!NWQR>G5/1.AZ9>KWO2R[^XR4YT\IV]U&:DY=-XVI;[2;6-N.G].:S[)L;_MQ!>#> M#"D-I]5> 3$W1$Q>$>U,1/4AN5\P/2G9B>ENL/PPY<(B-I@3W8E05F;KQ/9?$"TNPYV M0DCK*(]PMJMJ7D]PAH'C+T_[:D^39%_8V- M1OTMI]O:F3+?EM,\6L$_V50*8K6-Y0U1TW9JM9R">E![\* 9L+DV(%O0_ 55 MH=L2[EP O2U"VDZKN3-E]DWGL+Y".<5VC<.I^R?H,+6;23R=G'@OD/W2[XO0=-74=/?=9I5W9[1F9P@!1WUW7..<7-D(W"XY:W>SG]W- M&>Q?[K_8 RHX4'#@8$&#@969L"'S>J^C=@U[U&ZN::FI,%PVY\8])4?/,4_% M8.K_INAN'RKU@B#@["[=Q6TL$=^^,Z'A=%I+=?B1,Z'=&!.:3:<^ MW^4@+Q,V%-R^3<_+G9OSK]L//>HZA^V=R:4?-9UF;6?JUH W MM<.=25L='CKMO*U6-A_UWF9LD^)^/#5*6GY/=JUX)'&5'.R:3T7N GK/-*P MZMG0U4\0I,JZKW>C)0S<\TO1J(H;B+;[6F]//F0:)]O[N$P-N#>2@33WEEZ) MZ2VBTK3M7W39S/XVG#>;?0E;LBPQ=^XLN$YUCR?[:)1Y ?UW]-IO%;WV,Y[# M<=%K_S[K8\\ZCJ^88EF]]6OJ D[;$;Z[T8[P/LFRHJUYT=:\:&M^BP!WNQ-T MT?CZ,4^WD.Y:VYJOIS/W&=ZJ0]>#K:U#]V+A+FO3[73FVQ]LJ6GTO2;0:LTI MR#Z1WP3^SQ53[M,$VO/=K+;;N3N!!WR=\>!SM E=6GR__[O/]^]@M'3+:O=G M7U0?',SO:10*L&LM0E>OM1 1U3O>X5KLX[XR>B5+_;Y;=Y576ZK[P(<%SLT3 MY$+3:<]W>GF"?%C@:MV+"P][Y&LSN_'+O[CK9U(+:K9G3V=C@MK"=,&B%,6S MD]-LWRV\]!:/I/+/I-.?+K+<&;EVG MN4JGW W5BCI'W4V>^RZRC??+-G5J2V.6QYQN.FAV[M_O[C',O^&TYB^9>%(< MJ#OU^6M9=^V\URR,-5:$L4P24B\WV7N=>G'J\ZT(GV *JN%TEROS$^!#O>,< M%0H!8QTZA_-.89&5W)MXKZ!FQV/A7Y8> &&1BKB_]O"OYM1V)S+N.O7=28>V MZDYM?J-N6]0TVDYKE0;..Q$:KWK3Q9IY=M#=C9;7ASMQ,V!GE:Y3&^C_O3M7 M A99GB59#J>[?&_Z44?YV(?R_O?B/08.0$A4JSUQ%C2,OYW@ M67X0^3&$LT6>)^%#<]XC>H)\:+2&PVS=-Q.H<[4T_5<;J=G4DY-=J @#O3*ZO>=8[R M4E-$R5N.$=OWO_[O,81'S?F4[9.:?]VIM9]X@.S4YB\^>!SQ<;C$?#^&(* # M4>']>]\^GF (G*3E95U/@ \0';>Z2S']"3""KF]]F+Q1$1T7U.PL-=N+CB\Q M^&4J[7 F;G0X6UO4UW(Z>;L KS7JZQ[N3$3Q_0$&-'! M [\/TW%FOQG1[#J=]@,?6?6E\_Y$(\5J2BH[P\@'X+AIU MH,H=!F"^!Q.*#W@PR5A6>Z5)\EU/7$E7.# P'P0*9N "/;31(@<2$T-#P?UH MR+1P(Q7J*A #\ASQ/U0HHTE%70=XV5$;$P-]RBF2>G,#&@G52Y%0Q[94[&:9O5.JU]B'GIT MQF$M.\(/Q$-X (YU_/F670D>J( !&"KRM)A)AD"HU*JN9MZ1+J]TX#($N8CUM M(B)-/)@A:SR<:$L9C&-G *M#:%CC\ H024\D3R# (67 98&$#9$!( D^GK"Q M"B.'70^E.RR7KB5HD,2V5WWN"C,15%=#W9GAY1GR\L+G$6C+:'\OW$FP=D_) M?Z]P(:G0W'^$"Y=^D0%*Q6HCFCAFL-EA8U]P+=B5U#)BQ]]/QOP*_EX%!3Y^ M]?VDD./6Y3@ONCD3-2]%'[_B_2S$N,-BS-JT>0E>X:?&K!52W'9WB MWK),0'MS7/J67B.YSFAX@_Q>(.W5;WK; M /F70ZDA,@DQML 0 TV%-#=?4GA&XO&->#*7?#**,&5PI?PKP<"@_""W,$:' M/>+@T4N(,MC[VY_GY$A.,G^R42M^$*B( 5T8(V&T ;%!!*-]B]WA'239H((& M,'N \5B9F-X&.!"A^%+T=7J#IQN1V=08+1FW]46H_XS5&XTQ8P#K'T=V:$@( M&O^ !S#0P>GJ^?DF!+@J]C$0A$"1 >4QS #8&_O(-06!9;\/04T_A%"-KE"] M=4)5]A5?5"[-O8G9^'YBWZ*1,V9@-!8ZD:"#V_HPIKF^-!K"^$ ER RF[4,\ MG.0\QL!G,<\$"C:!A1KW5=^42\EY3 $QHQK9>\U-E@'#2$\2,]_0D+/TRF H M2 +PPMNJ5AU+-3*!A*9LZB "#8:G3!-DT!+%N'>%H>%-A\F+7L#D4@QBF MJ<()2FXD-42O =BKH2!>9#[F<33$[ #22?$HQ+&X;ZPIEY2&I";2I7[, 5"1 M2)3D>)-MO@Q(<9%ZS%HDO^L(IB?TE S\ OPT!=G*)6JU9V2-:S.F.^P9 MURP0PH.GC;X:E:-=^$C2D=V,J#$[$Z2C./9]; B#] 1P(Y,@0=:???GMPWFE MW@4['G@B43Q27/N'E%0Y&L.2@QDFF=;TDQZF6@#E$)X^*1 M+DB406 +@RC0%TQ[F$R3)UWB;1S"VO0G5N\Q>]A',D8&<\0$UL 1A,1\7]H%!*KKAG*, M;RZ7#,G:#&7O-1YA4H;#\KR-I!1O.&",&]U4D'X/(S8 M!X=] $!C]5.'O? ]? !AK5QZ;]COO CICP@--X8=(0+ \D'@. T"!-*O DG% M]!O,%0:M5?[-^M+/+M1O N1DEC,E,G^Z0QZ )W<&2FY@P$%MQ:]J/A*X=B:X MYN.QQR-SW;,A_!;*F24\0S>JPG]B>$A@_G*>QO]8&F$%)_G_?H2,CV8F62[- MS+*:?-F3VO6Y'&EZ$:;+3 H8I*UZX%J8V \5(89?72#!S 6_$(HK6K&4N[S% MTAB\[&,:EU'ZV'(,9H84SEI*O :;4>X5I#Q%?0<_<67HQB-- (0P8PTB )46 ML\-8GI.=ID=O:ABECWWY RSV4"G/?'[#FA):S]I3?!&N.%!<(\HE)O81>)@[ M1.DQ7B1_)=!Q,U;@$P 3AY4' G&CU_OBTF]DS_$A"?X$JXP+'VP>N %Z'RC. M;(/.)1WW@?[64:O:;'>JAW5L-KW[]([$^/]E$_#KHGA-&\K/5DJ1==ZP+^3E MZ-?L(P>S6F3,EF3,UI[N6K\=?/7VR_GO)_C#KY>?/I[\'U!+ P04 " . M0&]6+TJX2,,4 #-JP "P &9O>LHS;) MSM[)SG[-R]'_^ET-]8A%54/_&A%C0@01738456]_C3AV*YJ)_"^_NW/4L:$> MU-7IUTC'MLUI(@B/'OEQ=UN4.Z M.*KJU,:Z3(:--%5_F@^?E0ZK-BU-#51E7_Q.$O$IT%"JC!J,5T[%W<) 57MF MU0.WJNU75:F1E,3T:WBX-88-^O/JB@QGH)!\/ZY=C*K;L^N/JL9M"^NT95A= M;,,<,D@'44&*2JDQ(%%*Y @^#O6-GIOPLE$$Z(/9VIR@I2RXB:FPQ%7R,1P M^WU" ;20)+^B15ISP:;B4.I7=&BTC;$YK-S"M,DK>@4!J-ZW*'5,4R-=HMMS MV[$ZO.VOA-^:6O:K+;WRB58 SS(T0F?VQ$L"*"JV%;4')J&SR8?B."MF;82H M($:EX53(AJ/;UF#V^'J%@:X WYE$!"I=%^XNA[5,W.L2)28;758G(23$9(0+ M H(5^(G8/T>V:FLD?Q1W?T)IE]@8,0A1\LM1>U\C14.W802C#2 D@F3WKZ\1 MF_3MN"LOXJQ=W -[]*]H%)VH1%-RJ$[L0W2%NR2'^DK_$%5*_)<'03I^N*W_ M1RJ=%@K7\(.1@*+115LGQ =&Z,.(P >?P"6@)(5AJ]]I?B ^$%@'@#W\5]9A M_ 9%&!@+:Q5=(?UO9/ @@*Q,2Z+A]D,+:Y0L 2K% M1KGT(#YX(LR%"9^6@2$]U#O8(O1!>N 2VP5"^;=EX)08+M<>K,042G.!-PUE M@*@]T,C72 N8+X=$P;110^U"E2ORC&I&%^O[[H=]0,!26YS-%;7GMU-4:FIX MD$.ZH1->J/9SC%^)Q18"_TM5%*+S9<'^A(I73A=@R2[']^T:DW$GEM%EO!(5 M$E$Q:1NCWR-(!ZJA*Z+F9G)#)#]BAZ-XH(MP>@WP2B3/F65F1_$ N:Q?D-#$ M J.!4+<&4P0YRC4\(("XVLYUN)1G:R[J+Y=8GRH1KYC)N:\1JG9!XKHBP>LJ M"-SMCAJ.Y?<&U?C17S*)5@ ! M_Z,WI(N.\^BW!]FA-LC5HM'M&GK=-N2G:VS=8 MZ;?[&)E$4_V ^0(<.3VVK"U7Y]@VK&F&7&(,)G&\LP'YY8!2F!M2S+\:L"=>X\2V[HSBTAY_LWR-S62OR$'6QU5;U'(*JD?P1 M-;$^#B/:PEU5 ZOR#2B\+E5?B-MI)/_??XLIX? HS@""ZV7FUPR_25FIURO5JW!7XPH)DCA3-O/WA?I9Y>JT4;W:W]TI%9$D'"2S1_'F MU.I=6TH$CQ)_7;R)^CJRUDFU=@F8 MAIM&@:>7&R-YTVNT\?$!^.Q_' ,8[R^2ST2_308 AB.\20.]L=*3(PZBIU:^ M:NSNU,K7U5IC RFXOJW5;PN,A$85@2QM@+Q$8@)5:T@\V%.^H.H):IR5-Y"R M<<4P5 J%8H-1)&83R0TD:17&Y:IQ9B[A[H[10C5B&I:-]M@'!'\3#/8^H38B M/>@46;R8*%]R"/1&H'^.H$)DP^+)KQQR=+ L66K,1W0DG9Y[2%"/_;Q(KB_[TT76/NRM +D0U- MPR8%A/S?7*?\R+:6[Z!'+%N5L>:/%_@_OHM_9"L3SM$;_L]OD+1:HV>X^$9K M*NVM*3?W42-ME;)TM,UR0;.75+&;?6[8/Z[OI8,0+)]9_;KA->:YL&&O7!5C M<]?,V&*Q%?8_:]53OSB\U2Z[O7(?R[:+'ALTQ,6P/XP(4U0WB:(E6Q K%1TT.^FI^)Y5+WH[I0H M&LH<*7.7/JCV?YV<7)PGPE#<;!L.BWS;Q+2,'A,_0.*]N5-^E?M6'T. M(]+T*@*1?#(=%24Q*:;3?X_)]=LFC9O\X"Z4]\%GQ'=PJ_:X_AE/V+W]CV&A MJMTA%CIW+)4JJLRF-F!!\9'=S $Q6IX_,*ZDOXQ1]Z?R\,.EW>?D<[990J7T M+^)4IL\]QXR+U2V3;CR35FKUY41QN6MJQH#M_/D[>#IH+GC<;<2F6'L;4_@$ M,854ZE4;>IYO55 4BU#J_;A0=2+.2:[6['3J3JZ94CH2FD4>CN4\@X9(/I$2 MW&&_Q(I*#1T5>D1W9L0)1K9S,T2NWD?+CKLT>]P5^TX^?VJ1;[(2FJLQH_-( M7CHXHHZ9MSO^!C'VUXEF&-8BV9&MV[LI;F]J%A]>&]3&VD_5G!_]RUR>"AF2 M*EX-<-B,&.@]D@?I+/Y%OFYX%H\W7"Z"1@M=6ZHNJR;64+E/9,=6>P156V 0 M$/IEE0;C!MFVX0T^L*>+'&/2C<_9K'?^>I0T^^^_,Y*8/@2>MXE&S(ZA$Z1S M#VX? ?-K#M,;"%L$@Q!2R)]M9O"WFA69: *0\X6A?#%H:&6:Z3!3XX^%X7A_ MP&F2*'V9(_ZFK H_B'EA@!B[9L/S6MRRJ125K)GI)E)A&!.3?4;RV60VFDR( MV>U^BJV/,I>DE5L\5_'"IS833@P+EMWX-@0+N=^09T& [&RQ[0=ZFRBH#G*4 MH M,;6_/V%:YCO:;11TVB&<]L MV0+08SZPA2\BK+/Q+T1XE!)T2G5A@9E9T M:.SP% 8JQ*28B^^7W/J>O_F,DOOW!)''Z$,JA)BDZJ%*YCG6UKVEVL#5+.?@ MZ%XPD\ZV7\I4NZNGM/LSX2F4K:--P] (UOGY_G'+9B9*C)FRZ63R\"WK)CPW M9@7"QR/-15 .$(A,QZ(.DPT@7=CI+Y24#EPYP>5#'7Q,:*U"?P791GMB&A5/ M:@@F)P85O\0V0^&N8$Q7YL:^"ZZ?:JHFA5#!$T)U@Y\!!]%_";H8%+(V6P*9 MBIJ^K2F_:N>ME4J@:7S^#O$SHLO%L>M1-RU[Q"2.BM*8^"GW96ZQ!H5/4HBY M-;?R9R,88"M_ O)'\N3/M<5OJ&!W^_!#A\S*MZJMUKQ(3JI-TK@SN#MO)U75G2>JPHH OO9YFA_=9Z6\\J)U5ZE^17P\+*T+NN#[I-0]MC MNT&V4[JQZY3E\(++E/@:'!3$%+R,M\IE3G_..O'KZ=B!*32[T9EJK#_X% MZ-&YETP^>!=N1J.+76/Z\))^/+LKEV1B(VNK@H+L#(GUE+3S)<>%J:8;#8 M;= /+^W!1;]V4W=^ZLMD]O[H+NY7M;4+QYW$G\@'QT(#/D#D0G39;2LL/X1W MI=7HZV48MS$X=TX=0RB?=3Z <6?H[9];7EP+;R='I?) M3OX92ZZ- M_NDPWK?+.NL+P&3$US@&2V:99U_X2>.X3?J#&QH56E"#H&+F88 MME';,I[M#LN/F&R/*Z9((2U5=Z]>W"0=^8'UB:QM\%;.)!-ICXY8^Y#O< MA -^K:;=@7Z =TQVUF6:1F5)H!+)!J<:$FAU!9QF74;@QL;,,F:O7< M9:GM3J@+HNRQR>[.!)],"M5$X+BDW^R4-RJZ;6;G/FVJ=M,I4BO2E>8^7\%K MX;3GELM6)\-:;(O]/*G$SK"Y,@X%19PZM5T?M!XB&I%M$&"ZP5.$#K@ K!90 MX!T*8(]6JCQMZ#X"PSB(]Z4-.*\_J] WXW(="( BB_14"@U!+F)=9MOPL,P? M3&2HLB=#%6PIU#T.H,Q+4";V\#!!.2[O8FC(?N\P93YWK.:=C4#Z8.;)J*2Y M+N]L+#9 JUDW'O3@!##:#@'(+X=M78"^7$*Y53T]ZJ\<.)NX8B7%;:11?GD\ MGSR9;P[V,9THGD@H3]O:H[#,S 38^'!HI,5;*!.,EDC\9S0-S&2&N"\9&19=C:(]9%>P2 E('N_U MM7/]GOWK#0]O+1Y^ 0>1.@ 7@SU#* 7C!PQJ,*&PKH/)P];\F!UD>:S%#"B5 M_50I+$;$WA?8W7&MK1*1W6<*$R+'7.*6M3V59\+R^^TS%!G!*'[RZ]V=7XCL97+SHIH1*L M,,U@;QMN)758"Q%\%3"BP><$X4'4W<,46=LNQ=)4RG39B!NIR ]-B3!*- M7^3CAC-<50>*D7,)B_42V]A'M(,UC0<_F@0IA# CP3,-6JI&%$_1V/LDSU M?[SG-O+/AIE'UW'S[%SZ<3; FO'ZWT3AGO)E=\>?X9 /LBQ":51<$[&U22=A M/O"^L/#%H,=\P[NRW^79%B$FKM0G7NUUM6$B7B)4ME0S\ 3&FFU^#)-<%JP) MA5'7D<1,EBL>&WWS(8Y%**07+OIV:0C M_$6CYU]_R%-3%;;Q#LO\>N02MC%BCX&@/1:\55@@EV7%P:MB+EI%9Q%D]/VX M=C%TL/[.T]"OIVBE;8IVFZ)=A%VWCVY['FV]BF21 %&J' T'G" ML$DZ6&NAYL"-_?'HIU>#Q3,='1IQ>-BQ.X8%Z"NKB>1]6&;N;W1R/\1I8L'F MG/^8#4^5'^P'[X,/HQN6>Y]MW\'HLL]?(]+2$Q?JLIYZ@'P]78$ALQ[P?87K M:8+[MLK:8YA,KQC%=6*=-9V,,-$Z'N2&#TPM'+[Z@SL\0C64U'R.XNJG"$VL*5.M*5HNCWB:VV>4+9-LT9JXUH^JRO ^/Y8$+794 MTAK;P^J^Z66M-@SUP1&GQ"&J\L0 S;EOD6P#4*L/0&W"+OZPKSOT <6;AC+@ M.PHZ=E?+![FS3L!]9F>#1 RQP_\N)7[. H?+MZ.G/?%1_'D MXOFE<--_R1[W,E>UUG%?D1Z[M[VN7JO<']2EQQ.M*6II63JQF]I+/=5(U1/9 M"K6;[;/2C_)-6D_'$Z+PXY%6?EYCX_1423OJRQ.E#4$0U,JM4[X[_8[/K,%Y MBMPFCGMM$O]V?][$_SB9PD_GYH=R^2RHW8QD.,>E72?TN?6'>EFO%?DD;.#^K ME_&7=N]6:+7KUP7C^]G3C[."0,Z2+ZW>O5I/%+Y^=:?E_P%02P,$% @ M#D!O5D@R\OGT P F@\ !$ !P879M+3(P,C,P,S$T+GAS9+U777/:.A!] M;F?Z'U2_&V-HFD*AG31,>IF&>[DA33I]Z0A[ 36VY$@RD/OK[TJV^89B^L&3 M+)US=E=::9?6^WD=SP/W8G#9[3KD_;L7SPG^ M6B]=EUPQB,(FZ8C [?*1>$O^IC$TR4?@(*D6\BVYHU%J9L05BT"22Q$G$6C MA'- MZA4AQUZM6O6]+[WK@<4Y&; YCQA_V 7W&XV&9U<+Z!9R/I11(5WWS/*0*E@H MXRH[@&=<:4)@OPB*JA%552NRI-+/BQ7L!Q=B=T3=-0]5,":K>J75HCA%IN$-;V#9<] MLVPX5;?JNS6_8/8O[GH+4D*G,80FFPVR7JW[K_!.1A #UU="QAT8T33" !Y3 M&K$1@] AFLHQ:).>*J$!'-0J,IQR+O BX&W,9\Q_L.)&@D&=]O\:)G)A#]I "&@5I5(ZS=&4G)9\H]FBY:\5MNH$1 ML;>P:0Z^[2AFWD$GGYM(&+4=LY%N<3C?,+0*YD0!,=(';J'=^40[U>$'-%AV9"1 M%OC/7:Z/_2 M(#&3R@:YGGR_*=+.PLAJN/EKX"V?@_Q[\\EH8>!":L*W7IY#)2,K=ME M*J^,QQC=R?$@TJJ8^2D7UNIP>4<>ZZM";C95VI?-?N X/XK6 'W(!4ZUCR&L M-@X_<1Y6IM2!_+@;V>?.CYCV6YUT(0*1+=INS/26W_ /6"SX0(O@H4^E_>M2K6 7U@4RDIU^I6]%,93/"I7HEB M/;Q2C#\;8LO+<@&'_P-02P,$% @ #D!O5I^!5-+^" ?6@ !4 !P M879M+3(P,C,P,S$T7V1E9BYX;6S575USVS86?=^9_0]<[;.L#\=MX\;M*(K= MT32)M9:;;/OB@4A(PA@"- !H2_^^ #]D4L0E*=>&R3PX,G4 G'L.".*2 /WA MU^V:>@]82,+916=PTN]XF/D\(&QYT?ECUAW-QI-)QY,*L0!1SO!%A_'.K[_\ M^U^>_O?A/]VN=T4P#D.QPOJ+N.%S[^QD\*/O=;LUZOV&6<#%'S>3?;TKI3;RO-=[?'P\8?P! M/7)Q+T]\OJY7X4PA%O__\GGFK_ :=0DSNOFXDY8RM=C*#=Z_?]^+ODVA!>1V+FC: MQFDOI;.O67\;J'V!+/BL%W^9A9*2JC.D)3F7422?N8]4U$,J&7D@POS636%= MM_J!CVL<6"<[9FO>F.N>Z[F&15: M";RXZ!B(KGMXVC\=O#,U_S<'4KN-[L&2F [8\7JY5I'PTX9MX&PK0(RIU":X MLZCQE:Y"^.$<=P.RQLQT]HZ7-)2-;%\+8:JGH;T$T[-6\/J\]XUU [Y&Y$C2 MQ=(.&$H)"J9W?* MM'B>LSY,&#'#W&?]:XXWWBI]U<%!RMQ46&]44D09:')%&7A=<_D)-1.E/\;( MA$1*@W(_US8U8R\71=%D&NT"R7D4IDND1,R(.(Q&3 W?F MHH<-#1TKGNB/,FV HCFF4;-W"=B&[;TMZULT?^I')8P3W"';)ZM'(N6=]).: M)V/<.<]]SI3N')?4!BZ!8+6Z] ME2]9BI^2:S)DB W[HDX4IP=5-H *\TKFD!7#?CN]N!M8B+^4'>F%\9^.;L_V M*XH.LNSTN985DX+IZ-N7.YV'KCF+6I\B$:5__1-]D9YB,5LA@;\D$\*".:9T MO<*OX%9^L@HX47(F\&?% (YHSQW2 $]F6! L__J.A$!,R5L^#86_T@ECAFNI M+_4KN+,- 8WQYL@XP&'N12XY$OLG2_[0"S")1SC]X6E@T[_(&+XE4(KJSN ^H?/"P%FFT"=7,P>F.6S=& MC(6(WN -%Q4F9)&MT+Y &)+\G5O)_Q.)BIY6 MR4BJ.N(?HENAOI4T)/\/;N6?K3"EYD$@8K5Z?Q'?"@L VI )/[Z="9ECML<$F4 *\%;(;V?]XC?4_I$%?V(D:ANP![=( M_CQG4'Q'&? X%")'K73D@="-EK^4-*B_HYSWDBFB=F8UVM<0N)>L88>H1NMM M)0OJ["C1C4FEMSZ8,@ONRK3.(UN@MX4PJ+FC!#6 ZQ+1#>2AE4WE$V&U.[1=M)H(,@"Q*O M5:TV "C2 A_*F(-V.$IG8X83YG.QX9G[W6,>ZK-V-^9!Z26@M& +K*GF#QKD M*.>->8Z"0& ID_],7(,R6RSP%I@!L08?@#G*?R%VP^,L&+;2@F&Y!8[R7XC= MZ7$6G+;2@M-R"QQEP3EV8_WQ6MSR1^#I.P!NC_P'G$'QG:; ";&VS$02^:JSXJST'O(AJM$:6\F".KM*5\W>.PD.#_NO&ZULGB4DZ;,W M.!PIZ7=!E.9C5I*'++F#!#SYLT(;+37,&)3=4 N/!=AHM2&^H.".,LH<*[O4.4BC12XR!>5UE%&F)]GEUE\A MML3PB@X;LM%B@X1!S1UEFD\#V[+66+ULTUB]K#%6.\HT4U+Q0GU]WEW/*5DB M>$=@28%6J _QAHRPQ?0:1L3[M6>9 M^O82+3"AA#CHA=.'IQ.FL$"^(@_X$U(HX5OFA;U$"[PH(0YZX73A<72BCG4\ M2UZ^=B ';('R1;Z@X$[7&\_6B-*/H=0!R-+Q)P=L@>!%OJ#@3E<47ZZQ6.IA M\#?!']4JV!K.*?&O*$>E\_X,K 5:'[(%I7::^7Y$ M[%Z$&^7OIH+[&)L'0W)_3M9(OFI5T )[ZL M'1<%:%DF]?[0.PA0-W^OOTN.FQ_F#\#H(W\#4$L#!!0 ( Y ;U;\8S&Q M\@L B0 5 <&%V;2TR,#(S,#,Q-%]L86(N>&ULS9UM;]NZ&8:_#]A_ MX+Q]V( XCI.]H#GM.4C3Y" X:9+5;KNU& I:IFTALAA0]H-+Q*%_0G=(/7 MY!3]2E+"<$[93^@33C9B"[V,$\+0.5T_)"0G?(GXJ_9C@CB)^O-#O=9O&;@3AN<=BGDT/*EJ/CHZ/QZ#_OKR?1BJSQ,$[% M>8O(0$>)4FQQXU>O7HWD7BUM*+<9/%I)NU=TPCG MLMD[#X- A?C?4,N&8M-P?#P\&1]NL_E GWQY!AE-R >R0+*:I_GS TO.Q,5R)_%]MYT_+>I]=^7A.Q\9I_JEDDVYP/8&2N38HB6GI@>00Y M,!1EEZ73J%9N(GISRIIU%R.C+'.!LYDL>),-EQ@_\ ,<'X](DF=ZRU!LD2>A MV/!-C(UD3=+\/,%9=KN8Y#2Z/]O&F3Z.K.2;00_]R*R B#QCNA:811VGHE", M(LH'LH=\F*B3KL(7C*Y[V2C.&>TA_I;,RO+52>86@(K49(QD=,,BLE<;5VO3 M]ZP6#M<)CQ 3-I(./TX&/TL9H@LDA>BKD/[O]6A7]$M8>L"/:P'(R=')^.\2 MDKNS3^^_\8R3G4T2&?!O'^?;+"C+PGZQEA1L7VBG0!S@NJ(A#: M(\P[3/M[;6 E@Q54!XC'JRDS^HLL O$RD"SD=R)MPF<,)/OR&3.&TSR;TCM^ M6E9\VEFI%$S;/M'.B-N_2B5U_4/#(&]OOR9]J@#T!>DB4$Z1+@15V?Q>_G[< MJ#G%L]UT!.K4"Y&7\;%FT#HH2H5WA%IM-4C1(O15RKY[Z/MQ0/#I(+GB'SOG M3Q6A%S :1JUPE*KP #&MM4 BI$AJ?RPI&8D.E_1Q-">Q@H1_V+'!__/M'8TV MDF9>HE&AYFX7'$"F1.N;^[RW.6#(;&DM04+CN('/^('GXN"7"5Y:[!O[736Q MU99NX]K.(!K9YLALY5*#A,A7,[\C6<3B!W%;M:T>-9GS1K>8;+1]11,6 DUC M, D5K:>._0-9QEG.Y'WVNNO]6V.198Q4% T\:"L#9^ZS#4U-I,F+%5-4(Q8C(%H*"U28D]$_'N#64Y8\MP)14/I MF@O JHF&(0N*#KLW$)!2[I>1*<-I%HL.K!.2IM3YY09@MG'I8>B"X@0P!U^2 ME'J_I$Q6)$G$Y0;&+7M,"&35Z:RJ"( >V!S,@(5(2$@\W%HYB=\VE2 MS\I6]#[A:=ANXZ<4!XN0Z; G13(,B3A/)%4>!^E@J*%T30]@U>3&D 5%C-T; MR(J2(ZGW#\E%.N^%2*GS XAATXY'(0H0CKJS+C2XVB<8EW$6X41YN>3;S)]7 M.K2N 0'MFI TA$&! KD#85$!FAD9XA68_Q+,^N%24?J!I6'5CDHI"Q 4TUL7 M)D+O!9+S#6,UU_"( TM=8=)E5G,"Z8( I<-6E[_2I#F8C$)6!U3YI8 N\DZ M!75-0"18C0$T[+1R;8\7(LYYS\1P1)''4-%4^@6#2 M*=Y>S3FH\2)6Z_(Z* 'U;F'IL%UG!A 'A$Z[0X @'H3J43Y!NDHCRAYHY7&' M<[KA'>#S.9W#,Y2.*+=0]:I"':W6D( Z^,3P*P6>J">24%4K*>6!2!1@A?B MSN9S?J*RXI_K."5CL/Y6K5NZ6NS6F;(( R()=@?P4R@/] :DZ"A.7D1-+SAO?8UY_SC M+9O2)]O#V:#2"S)-JU9@=K+P<&EXZX)%!(CYC CQB8F<6-VR.T8?XS2"I\R0 MW LP@&DK-88V/'3L!KOX*2?$.LYK7Z,FY9U?$BWST\O43=J[&*4)#Y*ZL<[. M1:E](G%'LQPG7^*'U@MQN]@+'E;#5DAJRO!0L=GK D;%(![DX\*ZP%7\H&%= M2F;L=_9KL\U6^1-S=6<0$-@<-;-:J+LG2N2ZF06CC&"@1ZCO=M;(%E-E&U?V MA='$34.-%I;?:Z[Q\4466?:2NQ5-X0<$FA)7+0V9TZUM[@^BQ0%39JM+&9(Z M3W?C1::OS-Y]5_8Y&]E-.^5 KG<$T;JFF\8PK?<[;LW/+,[YD46>F4U:_,IC M>VX0T+EJY5:;NL6MHB!:O\V924*A176Q8RPF-(FC.(_3Y7M^\0* M"-B@IJ&I" (%T%8CDTLI1%KI&(([)K-8$=X0L# *23GLF+#Q@&%4BD I!,L8O-E=9MB%L+W@L(9X0 LT#(#7T(>($F>R$ M2@7Z9&M"H@T?'Y_'Q[-IG#>2T-DESL8DP%PY(AG[@V #,&6R(/>)W*OCX[_. M_H9TE./FOZ%3AD42_\GS>D83(/N45>4*@A:+F@.+) @48%\F#3<4%5*DM#ZR M4]7,6JIC['<%@-66;OK:SB :W>:H\>6OM;6G+O]B&ZVX*0(L2+#+7'?]-I-F M]U_5!(% B[%FMEHE15KK8T'";LA:=D\"EMXF YDMP.O1A,-3/9 ,G%:9S&9:!NU27KF^EJP

4L:P" R5&Y9L%JLLU"3!,2" MS1? @I0BK?7"PL6:L"4?WGYE]"E?%?E9P;H!:K=LM%JN,V*5!L1*FS^ &1V" M5(Q.J>L'GNTNH;C*L@C7U")UC UHUF"FH0L)&,A<@Y:$1.)^RPW-T92BCQE! M^8J@B^)UP-5,\*H<7V\:B2*Q($+-RM,Y9C:$VL3.WSH"&FZ\>Z2A# *D3GOP M>TC*"*1#'%-SRQEFU>LX:4*\2P]<[= =XHJ@ON8U1UWZ(&CJ:=)D2H;5+ZYE MH'POHL]L1M7D]O 4KR9R/#.V�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end